Loading
Loading
Resveratrol was once the darling of the anti-aging world, propelled by David Sinclair's high-profile research on sirtuins and red wine compounds. Life Extension's formulation combines trans-resveratrol with quercetin and other polyphenols. The reality: resveratrol has poor bioavailability in humans, the Sinclair-linked company (Sirtris) was acquired by GSK for $720M and then shuttered, and human clinical trials have been largely disappointing.
Life Extension Optimized Resveratrol scores 58 with a hype penalty of 8 — the highest hype penalty in the longevity category. This reflects the enormous gap between the media narrative around resveratrol and the actual human evidence. The Sinclair/sirtuin story drove billions in investment and public interest, but the clinical data has been largely disappointing. The bioavailability problem is fundamental: <1% of oral resveratrol reaches systemic circulation. Life Extension adds quercetin and other polyphenols to improve the formula, but this does not solve the core bioavailability issue.
Resveratrol's rise and fall is one of the most instructive stories in supplement science. Howitz et al. (2003, Nature) reported resveratrol activated SIRT1, launching a decade of hype. Baur et al. (2006, Nature) showed resveratrol improved health and survival in obese mice. However, Pacholec et al. (2010, Journal of Biological Chemistry) demonstrated the original SIRT1 activation assay was an artifact — resveratrol did not directly activate SIRT1 as claimed. GlaxoSmithKline acquired Sirtris Pharmaceuticals for $720M in 2008 based on this research, then shuttered the company by 2013 after clinical failures. Human trials have been disappointing: Poulsen et al. (2013) found no metabolic benefits in obese men at 1500mg/day for 4 weeks. Vaz-da-Silva et al. (2008) showed resveratrol has extremely poor oral bioavailability (<1%). A few positive human studies exist (Timmers et al., 2011, Cell Metabolism) but the overall picture is far weaker than the preclinical excitement suggested.
| Ingredient | Dose | Verdict |
|---|---|---|
| Trans-Resveratrol | 250mg | Underdosed |
| Quercetin | 150mg | Underdosed |
| Fisetin | 10mg | Underdosed |
Why the true cost is higher
This product has 3 underdosed and 0 unknown-dose ingredients. To actually get clinically effective doses, you would need approximately 3 servings per day -- making your real cost $1.20 per effective dose instead of the listed $0.40.
Save $31.50/month (88%)
by switching to NOW Foods Quercetin 500mg
Oral bioavailability is extremely poor (<1%) — most resveratrol is rapidly metabolized before reaching target tissues. The original sirtuin activation claim was shown to be an assay artifact (Pacholec et al., 2010). GSK's $720M acquisition of Sirtris and subsequent shutdown is a cautionary tale about preclinical hype. Human clinical trials have been mostly negative or showed only modest effects that may be attributable to general polyphenol activity rather than resveratrol-specific mechanisms. The Sinclair controversy has damaged scientific credibility of the entire resveratrol field.
Biorank may earn a commission from qualifying purchases. This does not influence our scores or rankings.
Better-rated options in Longevity & Anti-Aging
Popular picks in Longevity & Anti-Aging